Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF, et al.
Lancet (London, England). Date of publication 2017 Apr 29;volume 389(10080):1756-1770.
1. Lancet. 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2.
Epub 2016 Dec 1.
Ulcerative colitis.
Ungaro R(1), Mehandru S(2), Allen PB(3), Peyrin-Biroulet L(4), Colombel JF(5).
Author information:
(1)Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New
York, NY, USA.
(2)Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New
York, NY, USA; Immunology Institute, Icahn School of Medicine at Mount Sinai,
New York, NY, USA.
(3)Division of Gastroenterology, Ulster Hospital, Belfast, Northern Ireland, UK.
(4)Department of Gastroenterology, University Hospital of Nancy-Brabois,
Vandoeuvre-les-Nancy, France.
(5)Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New
York, NY, USA. Electronic address: jean-frederic.colombel@mssm.edu.
Ulcerative colitis is a chronic inflammatory disease affecting the colon, and
its incidence is rising worldwide. The pathogenesis is multifactorial, involving
genetic predisposition, epithelial barrier defects, dysregulated immune
responses, and environmental factors. Patients with ulcerative colitis have
mucosal inflammation starting in the rectum that can extend continuously to
proximal segments of the colon. Ulcerative colitis usually presents with bloody
diarrhoea and is diagnosed by colonoscopy and histological findings. The aim of
management is to induce and then maintain remission, defined as resolution of
symptoms and endoscopic healing. Treatments for ulcerative colitis include
5-aminosalicylic acid drugs, steroids, and immunosuppressants. Some patients can
require colectomy for medically refractory disease or to treat colonic
neoplasia. The therapeutic armamentarium for ulcerative colitis is expanding,
and the number of drugs with new targets will rapidly increase in coming years.
Copyright © 2017 Elsevier Ltd. All rights reserved.
DOI: 10.1016/S0140-6736(16)32126-2
PMCID: PMC6487890
PMID: 27914657 [Indexed for MEDLINE]
Conflict of interest statement: Declaration of interests RCU has no conflicts of
interest. SM has served as a consultant for Pfizer Inc and receives research
funding support from Takeda Pharmaceuticals. PBA has received Speaker fees for
MSD, AbbVie, Allergen, Ferring, Warner Chilcott, and Napp. LP-B has received
consulting fees from Merck, AbbVie, Janssen, Genentech, Mitsubishi, Ferring,
Norgine, Tillots, Vifor, Therakos, Pharmacosmos, Pilège, Bristol-Myers Squibb,
Union Chimique Belge (UCB) Pharmaceuticals, Hospira, Celltrion, Takeda,
Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, HAC Pharma, Index
Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera,
and Samsung Bioepis, and lecture fees from Merck, AbbVie, Takeda, Janssen,
Takeda, Ferring, Norgine, Tillots, Vifor, Therakos, Mitsubishi, and HAC Pharma.
J-FC has served as consultant or advisory board member for AbbVie, Amgen,
AstraZeneca, ABScience, Boehringer, Bristol-Meyers Squibb, Celgene, Celltrion,
Danone, Enterome, Evidera, Ferring, Genentech, Giuliani SPA, Given Imaging,
Janssen & Janssen, Immune Pharmaceuticals, Intestinal Biotech Development, Kyowa
Kirin Pharma, Lilly, Medimmune, Merck Sharp Dohme, Merck & Co, Millennium
Pharmaceuticals Inc, Navigant Consulting, Neovacs, Nestle Nutrition Sciences
Partner, Nutrition Science Partners Ltd, Pfizer, Prometheus Laboratories,
Protagonist Therapies, Receptos, Sanofi, Schering Plough Corporation, Second
Genome, Shire, Takeda, Teva Pharmaceuticals, Tigenix, UCB, UEGW AbbVie Advisory
Board, UEGW AbbVie Symposium, Vertex, and Dr August Wolff GmbH Co.
